5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 17.61▲ | 17.87▼ | 17.89▼ | 17.52▲ | 16.72▲ |
MA10 | 17.74▼ | 17.91▼ | 17.92▼ | 17.26▲ | 15.45▲ |
MA20 | 17.85▼ | 17.92▼ | 17.85▼ | 16.64▲ | 14.13▲ |
MA50 | 17.91▼ | 17.57▲ | 17.20▲ | 15.09▲ | 13.52▲ |
MA100 | 17.92▼ | 17.18▲ | 17.18▲ | 13.80▲ | 10.32▲ |
MA200 | 17.86▼ | 17.06▲ | 15.89▲ | 13.67▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.029▼ | -0.045▼ | -0.040▼ | 0.031▲ | 0.383▲ |
RSI | 35.772▼ | 43.272▼ | 50.724▲ | 60.874▲ | 64.060▲ |
STOCH | 21.982 | 55.191 | 59.427 | 52.697 | 83.702▲ |
WILL %R | -58.824 | -61.111 | -49.007 | -37.771 | -16.828▲ |
CCI | -56.205 | -358.147▼ | -144.538▼ | 68.551 | 146.776▲ |
Thursday, July 10, 2025 07:18 AM
ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, is poised as a game-changer for emergency allergies, driving growth. Learn more on SPRY stock here.
|
Wednesday, July 09, 2025 11:08 AM
Find the latest on short interest, settlement dates, average share volume, and days to cover for ARS Pharmaceuticals, Inc. Common Stock (SPRY) at Nasdaq.com.
|
Wednesday, July 09, 2025 10:17 AM
ARS Pharmaceuticals targets 80% U.S. commercial coverage by year-end and is expanding internationally. Click here to find out why SPRY stock is a Hold.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
11/07/25 | 17.965 | 18.01 | 17.47 | 17.68 | 938,046 |
10/07/25 | 17.93 | 18.05 | 17.2875 | 17.98 | 1,431,052 |
09/07/25 | 17.12 | 17.94 | 16.96 | 17.90 | 1,209,044 |
08/07/25 | 17.44 | 17.44 | 16.40 | 16.95 | 1,297,085 |
07/07/25 | 16.58 | 17.90 | 16.44 | 17.09 | 1,657,120 |
03/07/25 | 16.75 | 16.81 | 16.15 | 16.52 | 881,491 |
02/07/25 | 15.86 | 16.76 | 15.75 | 16.75 | 1,285,251 |
01/07/25 | 17.14 | 17.4099 | 16.00 | 16.09 | 1,866,225 |
30/06/25 | 18.43 | 18.50 | 16.16 | 17.45 | 3,160,618 |
27/06/25 | 18.19 | 18.90 | 18.11 | 18.20 | 3,884,211 |
|
|
||||
|
|
||||
|
|